Unum plays its first glimpse of human data in an $86M IPO, revealing two deaths and an FDA hold
After promoting one of his top execs to president and bringing in two new board members, Unum Therapeutics CEO Chuck Wilson ended the week by putting the first snapshot of positive human data from their lead cell therapy for cancer on display in an $86 million IPO filing. But with just a handful of patients in the first round of clinical trials, Unum is also revealing publicly for the first time that it ran squarely into lethal rates of dose-limiting toxicity that killed two patients in one arm and forced it to abandon their high dose after the FDA slapped a clinical hold on the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
